Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Mind Medicine (MindMed) Inc
N.MMED.WA
Primary Symbol:
MNMD
Alternate Symbol(s):
N.MMED.WS
|
N.MMED.WR
|
N.MMED
Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen...
drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MNMD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 07, 2022 7:30am
New Press Release - MindMed to Participate in H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C...
read article.
(8)
•••
Tailslogan
X
View Profile
View Bullboard History
Comment by
Tailslogan
on Aug 29, 2022 9:12am
RE:1 for 15 shares, an investor's nightmare
That's why they make 11 foot poles....see ya loser
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Aug 29, 2022 8:22am
Mindmed Completes 15-To-1 Reverse Split To Maintain Nasdaq C
Mind Medicine might be slightly more volatile over the next few sessions. The psychedelic firm late on Friday announced that it has completed its previously announced reverse split, significantly
...more
(5)
•••
jazzlistener2
X
View Profile
View Bullboard History
Post by
jazzlistener2
on Aug 28, 2022 4:55pm
1 for 15 shares, an investor's nightmare
company is poorly managed and quite inept. I wouldn't touch this company with a ten foot pole. Hope they go bankrupt and do the world a favour. What a creepy company.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 26, 2022 4:30pm
New Press Release - MindMed Completes 1-for-15 Reverse Share Split
- Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 -NEW YORK, Aug. 26, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to...
read article.
(7)
•••
GreenStockNews
X
View Profile
View Bullboard History
Post by
GreenStockNews
on Aug 25, 2022 4:00pm
Mind Medicine ($MNMD) Doses First Patient in Phase 2b Trial
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Aug 25, 2022 8:51am
Mind Medicine Begins Phase 2B Study On Treating Anxiety
Mind Medicine has officially seen patient trials under a Phase 2b study get underway as it looks to find a treatment for generalized anxiety disorder. The firm this morning indicated it has begun
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 25, 2022 7:30am
New Press Release - MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its Phase 2b dose...
read article.
(1)
•••
OTCLegenda
X
View Profile
View Bullboard History
Post by
OTCLegenda
on Aug 23, 2022 10:34am
development of psychedelic medicines called psychoplastogens
On August 10, Charles Duncan at Cantor Fitzgerald initiated coverage on Mind Medicine stock with an Overweight rating and a target price of $3. The analyst believes that the drug pipeline of Mind
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 23, 2022 9:59am
New Press Release - IIROC Trade Resumption - MMED
TORONTO, Aug. 23, 2022 /CNW/ - Trading resumes in:Company: MIND MEDICINE (MINDMED) INC.NEO Exchange Symbol: MMEDAll Issues: NoResumption (ET): 9:39:10 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 23, 2022 9:51am
New Press Release - IIROC Trading Halt - MMED
TORONTO, Aug. 23, 2022 /CNW/ - The following issues have been halted by IIROC:Company: MIND MEDICINE (MINDMED) INC.NEO Exchange Symbol : MMEDAll Issues: YesReason: Single-Stock Circuit BreakerHalt Time (ET): 09:34:10 AMIIROC can make a decision to impose a temporary suspension (halt) of trading...
read article.
(220)
•••
MrVerbatim9800
X
View Profile
View Bullboard History
Post by
MrVerbatim9800
on Aug 18, 2022 12:48pm
Why Mind Medicine (MindMed) Stock Is Crushing It Today
Mind Medicine (MindMed) (NASDAQ: MNMD) stock is absolutely crushing it on Thursday, with shares soaring 45.4% as of 11:20 a.m. ET after rising as much as 77.3% earlier in the day. The
...more
(264)
•••
sollmg
X
View Profile
View Bullboard History
Post by
sollmg
on Aug 18, 2022 11:20am
MSN Article
Article. talks about short squeeze and $3 pre-split price target https://www.msn.com/en-us/money/topstocks/is-mindmed-mnmd-stock-the-next-big-short-squeeze/ar-AA10NTGK
(220)
•••
MrVerbatim9800
X
View Profile
View Bullboard History
Comment by
MrVerbatim9800
on Aug 18, 2022 10:50am
RE:Mind Medicine (MNMD) Stock: Why It Surged Over 70% Today
Love it..... ;)
(220)
•••
MrVerbatim9800
X
View Profile
View Bullboard History
Comment by
MrVerbatim9800
on Aug 18, 2022 10:26am
RE:What is happening today?
Losses cut by nearly 1/3 ! That's awesome. New CEO that actually has drive and getting us out there again. Recognition that we need to increase our position for the listing etc..... Lot's of
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
One Property, One Focus on Advancing this Gold Project in Ontario